1. Home
  2. CRDL vs CMCM Comparison

CRDL vs CMCM Comparison

Compare CRDL & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.57

Market Cap

226.6M

Sector

Health Care

ML Signal

N/A

Logo Cheetah Mobile Inc. each representing fifty (50)

CMCM

Cheetah Mobile Inc. each representing fifty (50)

N/A

Current Price

$2.86

Market Cap

88.8M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CRDL
CMCM
Founded
2017
2009
Country
Canada
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
226.6M
88.8M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
CRDL
CMCM
Price
$1.57
$2.86
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $8.37
N/A
AVG Volume (30 Days)
★ 1.1M
7.1K
Earning Date
11-12-2026
09-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$23.52
Revenue Next Year
N/A
$19.21
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$2.50
52 Week High
$2.34
$9.15

Technical Indicators

Market Signals
Indicator
CRDL
CMCM
Relative Strength Index (RSI) 37.68 48.50
Support Level $0.96 $2.89
Resistance Level $1.71 $3.51
Average True Range (ATR) 0.09 0.16
MACD -0.05 -0.02
Stochastic Oscillator 8.84 50.00

Price Performance

Historical Comparison
CRDL
CMCM

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The companies products and services includes Robotic Products, Global to B Services etc. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC.

Share on Social Networks: